Results 11 to 20 of about 20,735 (212)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19 [PDF]

Annals of Neurology, 2021
The global SARS‐CoV‐2 pandemic has contributed to more than 163 million confirmed infections and 3.3 million deaths worldwide. The severity of the pandemic has led to an unprecedented effort to develop multiple effective vaccines. Due to excellent safety and efficacy data from clinical trials, several vaccines were approved.
Frédéric Zuhorn, Tilmann Graf, Randolf Klingebiel, Wolf‐Rüdiger Schäbitz, Andreas Rogalewski   +4 more
openaire   +2 more sources

Haemophagocytic lymphohistiocytosis after ChAdOx1 nCoV-19 vaccination [PDF]

Journal of Clinical Pathology, 2021
We report three cases of haemophagocytic lymphohistiocytosis (HLH) following the ChAdOx1 Astrazeneca vaccine. HLH is a rare but often fatal dysregulated hyperimmune response that clinically resembles sepsis.1 It is classified as either familial, with known genetic defects in lymphocyte cytotoxicity identified (such as PRF1 or UNC13D mutations) or ...
Luke Attwell, Than Zaw, Jill McCormick, Jonathan Marks, Helen McCarthy   +4 more
openaire   +2 more sources

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination

BMJ Case Reports, 2022
Adverse events occurring after SARS-CoV-2 vaccination have been reported and are the subject of ongoing research. We present the case of a young woman with fully reversible radiculomyelitis, which happened after the first dose of the ChAdOx1 nCOVID-19 vaccine.
Rossella Spataro, Giacomo Fisco, Vincenzo La Bella   +2 more
openaire   +5 more sources

From Immunization to Autoimmunity: A Deep Dive Into Post-COVID-19 Vaccine Reactions-A Narrative Review. [PDF]

Health Sci Rep
ABSTRACT Background and Aims Coronavirus disease‐2019 (COVID‐19) emerged in 2019 from Wuhan, China, leading to the accelerated development of vaccines, which have proven instrumental in controlling the spread of the virus. While vaccination ceased the increasing trend of the viral infection, rare adverse autoimmune events emerged as important ...
Yousefi-Hashemabad MJ, Hashemi S, Saleki K, Nourbakhsh SMK, Saleki A, Hassanzadeh Z, Azadmehr A.   +6 more
europepmc   +2 more sources

ChAdOx1 COVID-19 vaccine-induced thrombocytopenia syndrome [PDF]

QJM: An International Journal of Medicine, 2021
COVID-19 vaccine remains critical to control the severe acute respiratory syndrome coronavirus 2 (SARS CoV 2), early recognition and management for COVID-19 vaccine associated side effects are imperative for physicians. COVID-19 vaccine-induced thrombosis with thrombocytopenia syndrome (TTS) is one of potential life-threating complication.
Y -H Wang, L -Y Huang, Y -L Chen, J -S Chan, W -F Chiang, C -Y Lin, M -H Chen, H -Y Shyu, P -J Hsiao   +8 more
openaire   +2 more sources

Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination [PDF]

Nature, 2021
Abstract Following severe adverse reactions in patients vaccinated with the AstraZeneca ChadOx1 (Chad) vaccine, European health authorities have recommended that patients under the age of 55 who received one dose of Chad vaccine receive a second dose of Pfizer BNT162b2 (BNT) vaccine as a booster.
Bruno Pozzetto, Vincent Legros, Sophia Djebali, Véronique Barateau, Nicolas Guibert, Marine Villard, Loïc Peyrot, Omran Allatif, Jean-Baptiste Fassier, Amélie Massardier-Pilonchéry, Karen Brengel-Pesce, Melyssa Yaugel-Novoa, Solène Denolly, Bertrand Boson, Thomas Bourlet, Antonin Bal, Martine Valette, Thibault Andrieu, Bruno Lina, Kahina Saker, Christelle Compagnon, Bouchra Mokdad, Constance d’Aubarede, Virginie Pitiot, Vanessa Escuret, Florence Morfin, Mary-Anne Trabaud, Margaux Prieux, Valérie Dubois, Laurence Josset, Soizic Daniel, François-Loïc Cosset, Stéphane Paul, Thierry Defrance, Jacqueline Marvel, Thierry Walzer, Sophie Trouillet-Assant   +36 more
openaire   +5 more sources

Effectiveness of COVID-19 Vaccination in Reducing Severity Among SARS-CoV-2 Infected Patients: A Prospective Study From Iraq. [PDF]

Health Sci Rep
ABSTRACT Background Coronavirus disease 2019 (COVID‐19) is a lethal global pandemic that originated in Wuhan, China at the end of 2019. As with other viral infectious diseases, the introduction of an effective vaccine is crucial for stopping the spread of the pandemic. In Iraq the COVID‐19 vaccination campaign started on March 2, 2021.
Al-Obaidi AH, Ibrahim MM, Al-Qaseer AHAM.   +2 more
europepmc   +2 more sources

A Rare Case of Guillain-Barré Syndrome following COVID-19 Vaccination

European Journal of Case Reports in Internal Medicine, 2021
Various vaccines against COVID-19 have been developed since SARS-CoV-2 emerged at the end of 2019. Their emergency administration in healthcare settings has been accompanied by numerous adverse effects.
Yash Kripalani, Vidyadhara Lakkappan, Lipeeka Parulekar, Anjum Shaikh, Rakesh Singh, Pradeep Vyas   +5 more
doaj   +1 more source

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women

Human Vaccines & Immunotherapeutics, 2023
This open-labeled non-inferiority trial evaluated immunogenicity and reactogenicity of heterologous and homologous COVID-19 vaccination schedules in pregnant Thai women.
Chenchit Chayachinda, Kanokwaroon Watananirun, Chayawat Phatihattakorn, Sanitra Anuwutnavin, Suvimol Niyomnaitham, Wanatpreeya Phongsamart, Keswadee Lapphra, Orasri Wittawatmongkol, Supattra Rungmaitree, Laddawan Jansarikit, Kobporn Boonnak, Patimaporn Wongprompitak, Sansnee Senawong, Avishek Upadhya, Zheng Quan Toh, Paul V. Licciardi, Kulkanya Chokephaibulkit   +16 more
doaj   +1 more source

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

Nature Communications, 2022
Abstract Small trials have suggested that heterologous vaccination with first-dose ChAdOx1 and second-dose BNT162b2 may generate a better immune response than homologous vaccination with two doses of ChAdOx1. In this cohort analysis, we use linked data from Catalonia (Spain), where those aged <60 who received a first dose of ...
Hermosilla, E, Coma, E, Xie, J, Feng, S, Cabezas, C, Méndez-Boo, L, Fina, F, Ballo, E, Martínez, M, Medina-Peralta, M, Argimon, JM, Prieto-Alhambra, D   +11 more
openaire   +5 more sources